@article{8ce7a83d5e184b208e589a7f7f6ec564,
title = "BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection",
author = "Clarke, \{Christina A.\} and Kathryn Lang and Girish Putcha and Beer, \{Jonathan P.\} and Maude Champagne and Andrea Ferris and Godsey, \{James H.\} and Grossman, \{Robert L.\} and Hoyos, \{Jody M.\} and Johann, \{Donald J.\} and Nancy Krunic and Peter Kuhn and Lee, \{Jerry S H\} and Tara Maddala and Marielena Mata and Jeremiah McDole and Omar Perez and Howard Scher and Stewart, \{Mark D.\} and Bhan, \{Seema Singh\} and Qu Zhang and Leiman, \{Lauren C.\}",
note = "Funding Information: The authors acknowledge the contributions to the BLOODPAC Project from Curran Shah from the University of Southern California as well as Donald Johann from the University of Arkansas and Robert Grossman from the University of Chicago for their critical review and thoughtful feedback on the study presented in this manuscript. We also wish to acknowledge the BLOODPAC Executive Committee and Scientific Co-Chairs. Executive Committee: Philip G. Febbo{\textemdash}Senior Vice President and Chief Medical Officer, Illumina; Robert L. Grossman{\textemdash}Professor, University of Chicago CTDS and Founder/Director, Open Commons Consortium; Peter Kuhn{\textemdash}Professor, University of Southern California; Anne-Marie Martin{\textemdash}Senior Vice President and Global Head of the Experimental Medicine Unit in Oncology Research and Development, GlaxoSmithKline; Jake Vinson{\textemdash}Chief Executive Officer, Prostate Cancer Clinical Trials Consortium. Scientific Co-Chairs: Kelli Bramlett{\textemdash}Director of R\&D, Thermo Fisher Scientific; Darya Chudova{\textemdash}SVP, Technology, Guardant Health; Jennifer Dickey{\textemdash}Head of Regulatory \& Quality, Personal Genome Diagnostics; James H. Godsey{\textemdash}VP, Advanced Dx R\&D, Quest Diagnostics; Jerry S.H. Lee{\textemdash}Chief Science and Innovation Officer, Lawrence J Ellison Institute for Transformative Medicine; Hakan Sakul{\textemdash}VP and Head of Diagnostics, Pfizer; Howard I. Scher{\textemdash}Physician and Head, Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center. Funding Information: Funding for this project was provided by the BLOODPAC Consortium and its members. The work described here was done through the BLOODPAC Consortium, which is a not‐for‐profit consortium consisting of members from industry, academia, not‐for‐profits, and US Government agencies, including companies that sell liquid biopsy assays, companies that use liquid biopsy assays as companion diagnostics, organizations that do research related to liquid biopsies, organizations that conduct clinical trials involving liquid biopsies, and agencies that develop policies and procedures related to liquid biopsies. In addition, some of the authors are employed by companies in the liquid biopsy field, have stock in companies in the liquid biopsy field, or consult with companies in the liquid biopsy field. The authors worked together collaboratively to develop consensus opinions and the authors do not have any particular or specific conflict with the work described in this paper, beyond those just enumerated. ",
year = "2023",
month = jan,
doi = "10.1111/cts.13427",
language = "English",
volume = "16",
pages = "5--9",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "John Wiley and Sons Inc",
number = "1",
}